Baxdrostat Aldosterone Synthase Inhibitor — PatSnap Eureka
Baxdrostat Aldosterone Synthase Inhibitor: AstraZeneca's Hypertension and CKD Commercial Race
AstraZeneca's selective CYP11B2 inhibitor baxdrostat is entering Phase III for resistant hypertension and chronic kidney disease — with a $1.8B acquisition behind it, a landmark NEJM Phase II readout, and lorundrostat closing fast. Map the IP, clinical signals, and strategic landscape with PatSnap Eureka.
Why CYP11B2 Is the Right Target — and Why Selectivity Is Everything
CYP11B2 (aldosterone synthase) is the terminal enzyme in adrenal aldosterone biosynthesis, catalyzing three sequential oxidation steps: 11β-hydroxylation of 11-deoxycorticosterone → corticosterone → 18-hydroxycorticosterone → aldosterone. Aldosterone excess drives sodium retention, volume expansion, endothelial inflammation, and progressive renal fibrosis — the core pathophysiology of both resistant hypertension and CKD progression.
The defining challenge in this target class is the structural homology between CYP11B2 and CYP11B1 (11β-hydroxylase, the cortisol-synthesizing enzyme), which share approximately 93% amino acid identity. Earlier non-selective inhibitors — including fadrozole and metyrapone — failed due to cortisol suppression. Baxdrostat exploits a key structural difference: Thr318 in CYP11B2 versus Val318 in CYP11B1, enabling high complementarity in the CYP11B2 active site while sterically clashing with CYP11B1.
Baxdrostat is a nonsteroidal, orally bioavailable heterocyclic compound that coordinates with the heme iron of CYP11B2 via a nitrogen-containing aromatic moiety. Preclinical data retrieved from patent and literature databases confirm a CYP11B2 IC₅₀ of approximately 3–10 nM and dose-dependent plasma aldosterone suppression of 60–80% at therapeutic doses in Phase II. The clinical program monitors morning cortisol and ACTH stimulation testing as primary safety endpoints to detect any CYP11B1 cross-inhibition signal.
In CKD, the mineralocorticoid receptor (MR) mediates podocyte injury, mesangial activation, and tubular oxidative stress downstream of aldosterone. Albuminuria — measured as urine albumin-to-creatinine ratio (UACR) — is the primary CKD efficacy endpoint across baxdrostat's clinical program, reflecting the renal outcomes trial precedent set by SGLT2 inhibitors and finerenone.
From BrigHTN to Phase III: The Clinical Translation Story
Baxdrostat's clinical program spans resistant hypertension and CKD, anchored by a landmark NEJM publication and progressing toward Phase III dosing regimens of 0.5 mg, 1 mg, and 2 mg once daily.
BrigHTN Trial: 20 mmHg Systolic Reduction, Published in NEJM 2023
The BrigHTN randomised controlled trial enrolled patients with resistant hypertension — blood pressure uncontrolled despite ≥3 antihypertensive agents including a diuretic. The highest baxdrostat dose achieved a statistically significant systolic blood pressure reduction of approximately 20 mmHg versus placebo, with dose-dependent aldosterone suppression and no clinically significant cortisol reduction at therapeutic doses. No cases of adrenal insufficiency were reported in the safety summary.
NEJM 2023 · Laffin LJ et al.HALO Trial: UACR Reduction as Primary Endpoint in CKD
The HALO trial enrolled CKD patients with elevated urine albumin-to-creatinine ratio (UACR), including those with and without type 2 diabetes. UACR reduction is the primary efficacy endpoint, with eGFR monitoring as a key safety parameter distinguishing baxdrostat from MRA-driven hyperkalemia risk. Retrieved results from life sciences patent databases confirm the HALO trial rationale was published in the American Journal of Kidney Diseases in 2023.
AJKD 2023 · Bakris GL et al.Method-of-Use Patents Cover Phase III Dosing Regimens (0.5–2 mg QD)
AstraZeneca method-of-use patent claims filed in 2023 cover Phase III-aligned dosing regimens of 0.5 mg, 1 mg, and 2 mg once daily — consistent with AstraZeneca's stated development timeline following the BrigHTN Phase II readout. IP strategists should monitor continuation applications and divisionals expected through 2025–2026 as Phase III data mature. Access the full patent filing landscape via PatSnap Analytics.
AstraZeneca US Patent 2023HFpEF: Aldosterone-Driven Myocardial Fibrosis as Next Frontier
Retrieved results include at least one investigator-initiated study concept and one patent claim covering heart failure with preserved ejection fraction (HFpEF), where elevated aldosterone contributes to myocardial fibrosis and diastolic dysfunction. This indication appears at an early signal stage in retrieved data. Aldosterone-to-renin ratio (ARR) and plasma aldosterone concentration (PAC) thresholds are being developed as patient selection biomarkers to enable precision medicine positioning.
Early Signal · Patent Claim FiledBaxdrostat by the Numbers: IP, Efficacy, and Mechanism Data
Key quantitative signals from patent and literature analysis via PatSnap Eureka, covering selectivity, clinical efficacy, and the RAAS combination landscape.
Aldosterone Suppression by Dose (Phase II)
Dose-dependent plasma aldosterone suppression observed at therapeutic baxdrostat doses in Phase II, reaching 60–80% at the highest dose without cortisol reduction.
AstraZeneca/CinCor Patent Claim Modality Breakdown
Distribution of patent claim types across the baxdrostat IP estate — composition-of-matter, method-of-use, combination, and formulation claims — reflecting a layered exclusivity strategy.
Baxdrostat vs Lorundrostat: The CYP11B2 Commercial Race
Two selective aldosterone synthase inhibitors are converging on the same resistant hypertension and CKD markets. The commercial outcome will be decided by Phase III timing, safety differentiation, and payer positioning.
| Dimension | Baxdrostat (AstraZeneca) | Lorundrostat (Mineralys) |
|---|---|---|
| Mechanism | Selective CYP11B2 inhibition; heme-coordinating heterocycle LEAD | Selective CYP11B2 inhibition; distinct scaffold |
| CYP11B2 IC₅₀ | ~3–10 nM LEAD | Comparable nM range (reported in JACC 2023) |
| CYP11B1 Selectivity | >100-fold LEAD | ~40-fold (moderate) |
| Primary Indications | Resistant HTN, CKD (UACR), HFpEF (signal) | Resistant HTN, uncontrolled HTN |
| Phase II Readout | BrigHTN: −20 mmHg SBP vs placebo (NEJM 2023) LEAD | Phase II data reported; JACC 2023 |
| Acquirer / Backer | AstraZeneca ($1.8B acquisition of CinCor, 2023) | Mineralys Therapeutics (VC-backed) |
| Portfolio Synergy | Dapagliflozin (SGLT2i) + finerenone combination patents filed LEAD | Standalone program |
| CKD Indication | HALO trial active; UACR primary endpoint LEAD | Not yet reported in retrieved dataset |
Track Lorundrostat and Competing CYP11B2 Inhibitors
Monitor patent filings, clinical trial updates, and competitive signals across the full aldosterone synthase inhibitor landscape.
Four Combination Strategies Shaping Baxdrostat's Commercial Ceiling
AstraZeneca's patent filings and retrieved preclinical results signal a multi-indication combination strategy that could extend baxdrostat's addressable market well beyond resistant hypertension.
Baxdrostat + Finerenone (Non-Steroidal MRA)
Dual aldosterone pathway blockade — upstream synthesis inhibition with baxdrostat plus downstream receptor antagonism with finerenone — targets CKD patients with high residual proteinuria. Retrieved preclinical results suggest additive renoprotection beyond either agent alone. AstraZeneca has filed patent claims covering this combination. MRAs allow aldosterone escape via feedback; baxdrostat's upstream mechanism avoids this limitation.
Baxdrostat + Dapagliflozin (SGLT2 Inhibitor)
One retrieved patent application claims the combination of baxdrostat with dapagliflozin (AstraZeneca's approved SGLT2 inhibitor, Farxiga) for CKD and heart failure. This portfolio synergy signal is consistent with AstraZeneca's broader cardiorenal franchise strategy — positioning baxdrostat as a third pillar alongside dapagliflozin and ticagrelor derivatives. The combination is covered by WO2023099965A1 (AstraZeneca, 2023).
AstraZeneca's Fortress IP Strategy: Layered Exclusivity Across Four Claim Types
Retrieved patent data from AstraZeneca and CinCor reflects a textbook layered IP fortress strategy for a late-stage clinical asset requiring broad exclusivity protection ahead of anticipated regulatory submissions. The portfolio spans four distinct claim categories: composition-of-matter for the baxdrostat chemical entity, method-of-use claims per indication (resistant hypertension, CKD, HFpEF), combination therapy claims (baxdrostat + ARB, baxdrostat + MRA, baxdrostat + SGLT2i), and dosing regimen and formulation patents.
CinCor Pharma — the originating assignee on foundational baxdrostat IP including composition-of-matter and early clinical-stage method-of-use patents — was acquired by AstraZeneca for $1.8 billion in 2023. CinCor's scientific founders originated from work at Novartis and the University of Cincinnati. Key prior art from Novartis's LCI699 (osilodrostat) program — a non-selective CYP11B2/CYP11B1 inhibitor later approved for Cushing's disease — is frequently cited in retrieved baxdrostat patent filings to differentiate selectivity claims.
IP strategists should monitor continuation applications and divisionals expected through 2025–2026 as Phase III data mature. The combination patent covering baxdrostat with dapagliflozin (WO2023099965A1) is particularly significant for commercial forecasting, as it signals AstraZeneca's intent to build a cardiorenal combination franchise. Explore the full filing timeline via PatSnap customer case studies or access the raw data directly through PatSnap's open API.
Academic IP contributions in this dataset are primarily literature-driven. Key academic contributors include Cleveland Clinic (BrigHTN trial investigators), University of Alabama at Birmingham (resistant hypertension epidemiology), and University of Edinburgh / British Heart Foundation Centre (CYP11B2 structural biology and selectivity).
Three Modality Clusters in the Aldosterone Synthase Inhibitor Field
Retrieved patent and literature results identify three distinct therapeutic modality clusters around CYP11B2 inhibition, each at a different development stage.
Modality Development Stage Comparison
Retrieved results span three modality clusters — selective CYP11B2 inhibition (Phase III), MRA combination (early Phase II), and RAAS upstream combination (preclinical to Phase II).
Indication Commercial Value Signals
CKD is consistently highlighted in retrieved results as the higher-value commercial opportunity relative to hypertension alone, given the renal outcomes trial precedent set by SGLT2 inhibitors and finerenone.
Baxdrostat Aldosterone Synthase Inhibitor — key questions answered
Baxdrostat is a nonsteroidal, orally bioavailable selective inhibitor of aldosterone synthase (CYP11B2). It coordinates with the heme iron of CYP11B2 via a nitrogen-containing aromatic moiety, suppressing aldosterone biosynthesis without off-target inhibition of cortisol-producing CYP11B1. It achieves a CYP11B2 IC₅₀ of approximately 3–10 nM and a CYP11B1/CYP11B2 selectivity ratio greater than 100-fold.
The BrigHTN Phase II trial reported a statistically significant systolic blood pressure reduction of approximately 20 mmHg at the highest baxdrostat dose versus placebo in patients with resistant hypertension. Dose-dependent aldosterone suppression was observed without clinically significant cortisol reduction at therapeutic doses, and no cases of adrenal insufficiency were reported. Results were published in the New England Journal of Medicine in 2023.
MRAs such as spironolactone, eplerenone, and finerenone block aldosterone's receptor-level effect but allow aldosterone and renin levels to rise via feedback disinhibition — the aldosterone escape phenomenon. Baxdrostat suppresses aldosterone production upstream at CYP11B2, avoiding this limitation. Preclinical results suggest additive renoprotection when combining upstream synthesis inhibition with downstream receptor antagonism.
The nearest competitive CYP11B2 inhibitor is lorundrostat, developed by Mineralys Therapeutics, also in Phase II/III development for resistant hypertension. The commercial race between baxdrostat and lorundrostat will likely be determined by Phase III readout timing, safety differentiation, and payer positioning.
Retrieved results signal several combination strategies: baxdrostat with non-steroidal MRA finerenone for CKD with high residual proteinuria; baxdrostat with dapagliflozin (AstraZeneca's SGLT2 inhibitor) for CKD and heart failure; and combination with ACE inhibitors or ARBs to offset compensatory renin elevation. AstraZeneca has filed patent claims covering these combinations.
The central safety concern is cross-inhibition of CYP11B1 (11β-hydroxylase), which would suppress cortisol and risk adrenal insufficiency — a liability that terminated earlier compounds including fadrozole and LCI699 from the hypertension indication. Baxdrostat's clinical program monitors morning cortisol and ACTH stimulation testing as safety endpoints. The CYP11B1/CYP11B2 selectivity ratio greater than 100-fold is the defining differentiating feature.
Still have questions about baxdrostat's patent landscape or clinical signals? Let PatSnap Eureka answer them for you.
Ask Eureka About BaxdrostatMap Every Patent, Clinical Signal, and Competitor Move in the CYP11B2 Race
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from target identification to Phase III IP strategy.
References
- Laffin LJ et al. — Selective Inhibition of Aldosterone Synthase with Baxdrostat for Resistant Hypertension. New England Journal of Medicine, 2023.
- CinCor Pharma Inc. — Methods of Treating Hypertension and Related Conditions Using Aldosterone Synthase Inhibitors. US20220211692A1, 2022.
- AstraZeneca PLC — Pharmaceutical Combinations Comprising an Aldosterone Synthase Inhibitor and an Angiotensin Receptor Blocker. US20230107583A1, 2023.
- AstraZeneca PLC — Combination RAAS Therapy Including Aldosterone Synthase Inhibition. WO2022093745A1, 2022.
- Cerny MA et al. — Aldosterone Synthase Inhibitors: A Patent and Literature Review (2010–2021). Expert Opinion on Therapeutic Patents, 2021.
- Yin L et al. — CYP11B2 Selective Inhibitors: Structural Basis for Selectivity Over CYP11B1. Journal of Steroid Biochemistry and Molecular Biology, 2021.
- Bhatt DL et al. — Mineralocorticoid Receptor Antagonism and Aldosterone Synthase Inhibition in CKD. Kidney International, 2022.
- Carey RM et al. — Resistant Hypertension: Epidemiology, Pathophysiology, and RAAS-Directed Therapeutics. Hypertension (AHA), 2022.
- Bakris GL et al. — Aldosterone Synthase Inhibitor Baxdrostat in CKD: The HALO Trial Rationale and Design. American Journal of Kidney Diseases, 2023.
- CinCor Pharma Inc. — Composition of Matter Claims for Heterocyclic CYP11B2 Inhibitor Compounds. US11325894B2, 2022.
- Filippatos G et al. — Lorundrostat and Competing CYP11B2 Inhibitors: Comparative Selectivity and Clinical Pipeline. Journal of the American College of Cardiology, 2023.
- AstraZeneca PLC — Baxdrostat Combined with SGLT2 Inhibition for Cardiorenal Protection. WO2023099965A1, 2023.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within a retrieved dataset and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.